Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Long-term follow-up of psilocybin-facilitated smoking cessation.

Johnson MW, Garcia-Romeu A, Griffiths RR.

Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60. doi: 10.3109/00952990.2016.1170135. Epub 2016 Jul 21.

PMID:
27441452
2.

Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.

Mooney ME, Schmitz JM, Allen S, Grabowski J, Pentel P, Oliver A, Hatsukami DK.

Clin Pharmacol Ther. 2016 Oct;100(4):344-52. doi: 10.1002/cpt.402. Epub 2016 Jun 20.

3.
4.

Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies.

Simmons SJ, Gould TJ.

J Clin Pharm Ther. 2014 Oct;39(5):457-67. doi: 10.1111/jcpt.12171. Epub 2014 May 14. Review.

5.

Varenicline for smoking cessation: A review of the literature.

Kaur K, Kaushal S, Chopra SC.

Curr Ther Res Clin Exp. 2009 Feb;70(1):35-54. doi: 10.1016/j.curtheres.2009.02.004. Erratum in: Curr Ther Res Clin Exp. 2010;71(1):89.

6.

Pharmacotherapy of smoking cessation.

Jiloha RC.

Indian J Psychiatry. 2014 Jan;56(1):87-95. doi: 10.4103/0019-5545.124726.

7.

Synthesis and activity of substituted heteroaromatics as positive allosteric modulators for α4β2α5 nicotinic acetylcholine receptors.

Jin Z, Khan P, Shin Y, Wang J, Lin L, Cameron MD, Lindstrom JM, Kenny PJ, Kamenecka TM.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):674-8. doi: 10.1016/j.bmcl.2013.11.049. Epub 2013 Nov 28.

8.
9.

Mind-body practices: an alternative, drug-free treatment for smoking cessation? A systematic review of the literature.

Carim-Todd L, Mitchell SH, Oken BS.

Drug Alcohol Depend. 2013 Oct 1;132(3):399-410. doi: 10.1016/j.drugalcdep.2013.04.014. Epub 2013 May 8. Review.

10.

Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature.

Carpenter MJ, Jardin BF, Burris JL, Mathew AR, Schnoll RA, Rigotti NA, Cummings KM.

Drugs. 2013 Apr;73(5):407-26. doi: 10.1007/s40265-013-0038-y. Review.

11.

A systematic review of the relationships between craving and smoking cessation.

Wray JM, Gass JC, Tiffany ST.

Nicotine Tob Res. 2013 Jul;15(7):1167-82. doi: 10.1093/ntr/nts268. Epub 2013 Jan 4. Review.

12.

Mirtazapine to reduce methamphetamine use: a randomized controlled trial.

Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, Shoptaw S, Vittinghoff E.

Arch Gen Psychiatry. 2011 Nov;68(11):1168-75. doi: 10.1001/archgenpsychiatry.2011.124.

13.

Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers.

Culbertson CS, Bramen J, Cohen MS, London ED, Olmstead RE, Gan JJ, Costello MR, Shulenberger S, Mandelkern MA, Brody AL.

Arch Gen Psychiatry. 2011 May;68(5):505-15. doi: 10.1001/archgenpsychiatry.2010.193. Epub 2011 Jan 3.

14.

Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial.

Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O'Malley SS.

Drug Alcohol Depend. 2010 Oct 1;111(3):200-6. doi: 10.1016/j.drugalcdep.2010.04.015. Epub 2010 Jun 12.

15.

Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review.

Hughes JR, Carpenter MJ, Naud S.

Nicotine Tob Res. 2010 Jul;12(7):756-62. doi: 10.1093/ntr/ntq078. Epub 2010 May 26. Review.

16.

Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis.

Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K.

Harm Reduct J. 2009 Sep 18;6:25. doi: 10.1186/1477-7517-6-25.

17.

Transplacental transfer and metabolism of bupropion.

Earhart AD, Patrikeeva S, Wang X, Abdelrahman DR, Hankins GD, Ahmed MS, Nanovskaya T.

J Matern Fetal Neonatal Med. 2010 May;23(5):409-16. doi: 10.1080/14767050903168424.

18.

Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment.

Fucito LM, Toll BA, Salovey P, O'Malley SS.

Psychol Addict Behav. 2009 Jun;23(2):373-9. doi: 10.1037/a0015695.

19.

The association among depressive symptoms, smoking status and antidepressant use in cardiac outpatients.

Gravely-Witte S, Stewart DE, Suskin N, Grace SL.

J Behav Med. 2009 Oct;32(5):478-90. doi: 10.1007/s10865-009-9218-3. Epub 2009 Jun 6.

20.

Psychological mediators of bupropion sustained-release treatment for smoking cessation.

McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Baker TB.

Addiction. 2008 Sep;103(9):1521-33. doi: 10.1111/j.1360-0443.2008.02275.x.

Supplemental Content

Support Center